Paul Choudhury Ratnadeep, Singh Akanksha, Mathai Eldho, Sudhakar Dgs, Tourneix Fleur, Alépée Nathalie, Gautier Francoise
L'Oréal Research & Innovation, Bengaluru, India.
L'Oréal Research & Innovation, Aulnay-sous-Bois, France.
J Appl Toxicol. 2024 Nov;44(11):1804-1815. doi: 10.1002/jat.4681. Epub 2024 Aug 2.
Skin sensitization is a key endpoint for safety assessment, especially for cosmetics and personal care products. The adverse outcome pathway for skin sensitization and the chemical and biological events driving the induction of human skin sensitization are now well understood. Several non-animal test methods have been developed to predict sensitizer potential by measuring the impact of chemical sensitizers on these key events. In this work, we have focused on Key Event 1 (the molecular initiating step), which is based on formation of a covalent adduct between skin sensitizers and endogenous proteins and/or peptides in the skin. There exists three in-chemico assays approved by the Organization for Economic Co-operation and Development-(1) Direct Peptide Reactivity Assay (DPRA), (2) Amino Acid Derivative Reactivity Assay (ADRA), and (3) Kinetic Direct Peptide Reactivity Assay (kDPRA) to quantify peptide/amino acid derivative depletion after incubation with test chemicals. However, overestimated depletion of the cysteine-based peptide/amino acid derivatives is known in such assays because of the dimerization of the thiol group. In this present work, we report the synthesis and structural confirmation of the dimer of N-(2-[1-naphthyl]acetyl)-L-cysteine (NAC) from the ADRA assay to allow simultaneous determination of (a) peptide depletion by quantifying NAC monomer and (b) peptide dimerization by quantifying NAC dimer thereby eliminating the overestimation. We present a case study with three chemicals to demonstrate the importance of this approach. Thus, this simultaneous assay gives a more informed view of the peptide reactivity of chemicals to better identify skin sensitizers.
皮肤致敏是安全性评估的关键终点,尤其是对于化妆品和个人护理产品而言。目前,人们已经充分了解了皮肤致敏的不良结局途径以及引发人体皮肤致敏的化学和生物学事件。已经开发了几种非动物测试方法,通过测量化学致敏剂对这些关键事件的影响来预测致敏剂潜力。在这项工作中,我们重点关注关键事件1(分子起始步骤),该步骤基于皮肤致敏剂与皮肤中的内源性蛋白质和/或肽之间形成共价加合物。经济合作与发展组织批准了三种体外化学分析方法:(1)直接肽反应性分析(DPRA),(2)氨基酸衍生物反应性分析(ADRA),以及(3)动力学直接肽反应性分析(kDPRA),用于在与测试化学品孵育后量化肽/氨基酸衍生物的消耗。然而,由于硫醇基团的二聚化,在这类分析中,基于半胱氨酸的肽/氨基酸衍生物的消耗被高估是已知的。在本工作中,我们报告了来自ADRA分析的N-(2-[1-萘基]乙酰基)-L-半胱氨酸(NAC)二聚体的合成和结构确认,以便通过量化NAC单体同时测定(a)肽的消耗,并通过量化NAC二聚体同时测定(b)肽的二聚化,从而消除高估。我们用三种化学品进行了案例研究,以证明这种方法的重要性。因此,这种同步分析能更全面地了解化学品的肽反应性,从而更好地识别皮肤致敏剂。